New technology for effective hemostasis correction has been developed at the National Research Center for Hematology by prof. Georgy Th. Guria group in collaboration with scientists from the Moscow Institute of Physics and Technology.
In contemporary clinical practice, thrombolysis is performed when thrombi formed in blood vessels pose a threat to a patient's life. Thrombolytic procedures themselves are associated with a high risk, as they can cause acute bleeding. Sometimes the necessity of thrombolysis appears urgently, for example in myocardial infarction and stroke. In these cases, onset-to-treatment time is a key limitation of thrombolytic therapy efficiency. Therefore, the implementation of a technique for early detection of coagulation onset is a matter of both a scientific and practical interest.
In the paper published in PLOS ONE, a new approach based on ultrasonic registration of blood coagulation in its early stages has been developed. Continuous ultrasonic monitoring of the blood’s aggregate state was performed using the in vitro blood flow model. An injection of fibrinolytic drug was performed automatically on the basis of ultrasonic data. The authors have shown that the ultrasonic monitoring technique allows detecting the stage of coagulation at which timely pharmacological intervention leads to a fast and complete dissolution of fibrin clots being formed in blood flow. The work opens new prospects for monitoring and timely preventing hemostatic disorders via wearable devices.
Authors are open for collaboration: guria@blood.ru
